Analysed BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ) News Sources
WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
14-08-2026
yahoo.com
bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
18-08-2026
yahoo.com
bioAffinity Technologies Signs Nationwide Federal Healthcare Distribution Agreement for CyPath Lung
18-08-2026
advfn.com
bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
20-08-2026
yahoo.com
bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors
01-09-2026
yahoo.com
bioAffinity Technologies Advances CyPath Lung for Post-Treatment Lung Cancer Surveillance
01-09-2026
advfn.com
bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
03-09-2026
yahoo.com
bioAffinity’s AI Lung-Cancer Stock Jumped Nearly 48% After a Reverse Split. What Would Have to Go Right?
05-09-2026
yahoo.com
What is the current price of BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ)?
The current price of BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ) is $0.152.
BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ) absolute price change since previous trading day?
The absolute price change of BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ) since the previous trading day is $-0.046.
BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ) percentage price change since previous trading day?
The percentage price change of BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ) since the previous trading day is -23.2323%.
What is the most recent average sentiment score for BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ)?
The most recent average sentiment score for BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ) is 73 out of 100.
What is the most recent average sentiment for BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ)?
The most recent sentiment for BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ) is .
SEC-8K** Filing Available For BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.